Engineered nanoparticles for the delivery of miRNA-125 inhibitors to manage influenza virus infection in chronic obstructive pulmonary disease (COPD)
Project Member(s): Oliver, B., Su, Q., Hansbro, P., Dua, K.
Funding or Partner Organisation: Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) (Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise)
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) (Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise)
Start year: 2021
Summary: This fellowship will allow me to explore the mechanisms by which miR-125 iNPs will suppress the pathogenesis of IAV infection in COPD. It will enable me to move a major step closer to developing new therapeutic strategies for this susceptible population. The opportunity to work alongside high-profile researchers will strengthen my expertise in chronic lung diseases and our collaborative network to apply for national and philanthropic grants. These opportunities will take my research to the next level, strengthening my career and ultimately providing substantial benefits to the community.
Publications:
Purohit, M, Gupta, G, Afzal, O, Altamimi, ASA, Alzarea, SI, Kazmi, I, Almalki, WH, Gulati, M, Kaur, IP, Singh, SK & Dua, K 2023, 'Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease', Chemico-Biological Interactions, vol. 371, pp. 110334-110334.
View/Download from: Publisher's site
FOR Codes: Pharmaceutical delivery technologies, Pharmacology and pharmaceutical sciences, Human Pharmaceutical Products